GB stock · Healthcare sector · Drug Manufacturers—General
Company Logo

GSK plc

GSKNYSE

33.97

USD
-0.39
(-1.12%)
Market Open
13.42P/E
9Forward P/E
0.67P/E to S&P500
69.092BMarket CAP
2.22%Div Yield
Upcoming Earnings
1 Feb-6 Feb
Shares Short
11/15/22
11.25M
Short % of Float
- -
Short % of Shares Outs.
0.55%
% Held by Insiders
0.03%
% Held by Institutions
13.83%
Beta
0.32
PEG Ratio
0.88
52w. high/low
46.97/28.47
Avg. Daily Volume
6.29M
Return %
Stock
S&P 500
1 year
(16.80)
(14.74)
3 years
(24.37)
26.05
5 years
(3.51)
50.86
Scale: |
High
Low
59.98
47.49
54.64
31.02
43.47
27.15
43.13
32.15
45.85
36.28
47.70
41.68
54.00
43.68
56.73
41.29
49.08
37.24
45.58
37.20
44.54
34.52
42.36
34.89
47.57
37.60
48.25
31.43
44.56
33.53
46.97
28.47
Currency:
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
10.28
10.32
11.72
13.99
13.96
13.62
13.45
13.72
11.96
12.38
14.35
15.45
15.68
17.06
17.13
17.05
16.95
Earnings per share
2.38
2.37
2.27
2.73
0.80
2.62
2.32
2.81
1.43
4.36
0.47
0.78
1.84
2.35
2.89
2.19
6.81
FCF per share
1.22
1.83
2.47
2.94
2.54
2.45
1.45
2.86
1.78
0.35
2.13
2.41
3.37
2.96
3.12
2.51
3.55
Dividends per share
1.15
1.27
1.45
1.52
1.58
1.69
1.94
1.90
2.00
2.00
2.49
2.00
2.00
2.00
2.00
2.00
1.87
CAPEX per share
0.70
0.97
1.00
0.92
0.80
0.66
0.77
0.88
0.91
0.98
1.21
1.13
0.91
1.09
1.12
1.46
1.06
Book Value per sh.
4.15
4.36
3.82
4.93
4.37
3.99
2.96
3.62
2.22
2.65
0.58
(0.03)
2.22
5.76
7.33
7.52
7.06
Comm.Shares outs.
2,259
2,203
2,078
2,028
2,034
2,011
1,965
1,932
1,923
1,932
1,944
1,954
1,966
1,979
1,990
2,001
2,010
Avg. annual P/E ratio
22.6
22.6
19.0
13.3
47.4
15.9
19.4
17.7
35.1
9.9
88.1
51.1
21.3
17.7
13.9
17.9
13.4
P/E to S&P500
1.3
1.3
0.9
0.2
2.3
1.0
1.3
1.0
1.9
0.5
4.0
2.2
0.9
0.7
0.4
0.6
0.7
Avg. annual div. yield
2.1%
2.4%
3.4%
4.2%
4.1%
4.1%
4.3%
3.8%
4.0%
4.6%
6.0%
5.0%
5.1%
4.8%
5.0%
5.1%
4.7%
Revenue (m)
23,218
22,739
24,352
28,368
28,392
27,387
26,431
26,505
23,006
23,923
27,889
30,186
30,821
33,754
34,099
34,114
34,065
Operating margin
33.6%
34.9%
29.3%
29.7%
13.3%
28.5%
28.0%
26.5%
15.6%
43.1%
9.3%
13.5%
17.8%
20.6%
22.8%
18.2%
17.2%
Depreciation (m)
958
1,023
1,231
1,562
1,679
1,423
1,445
1,414
1,484
1,630
1,774
1,922
1,856
2,334
2,351
2,377
2,657
Net profit (m)
5,387
5,219
4,712
5,531
1,634
5,261
4,565
5,436
2,756
8,422
912
1,532
3,623
4,645
5,749
4,385
13,742
Income tax rate
29.5%
29.5%
29.2%
28.2%
41.3%
29.1%
29.1%
15.3%
4.6%
20.5%
45.2%
38.5%
15.7%
15.3%
8.3%
6.4%
6.2%
Net profit margin
23.2%
23.0%
19.3%
19.5%
5.8%
19.2%
17.3%
20.5%
12.0%
35.2%
3.3%
5.1%
11.8%
13.8%
16.9%
12.9%
42.7%
Working capital (m)
3,726
3,284
7,252
5,452
3,242
1,157
(123)
1,550
1,383
3,170
(2,290)
(10,662)
(5,564)
(4,559)
(1,901)
(4,996)
(704)
Long-term debt (m)
4,770
7,074
15,231
14,786
14,809
12,203
14,671
15,456
15,841
15,324
14,661
14,264
20,271
23,590
23,425
20,572
19,322
Equity (m)
9,383
9,613
7,931
10,005
8,887
8,032
5,810
6,997
4,263
5,114
1,124
(68)
4,360
11,405
14,587
15,055
9,152
ROIC
31.5%
27.3%
18.3%
20.4%
7.7%
23.3%
19.3%
22.1%
12.9%
24.8%
3.8%
8.5%
12.0%
11.3%
12.7%
10.5%
35.7%
Return on capital
31.8%
25.7%
19.2%
20.3%
9.1%
20.6%
17.9%
17.4%
9.0%
22.8%
4.5%
6.9%
8.8%
8.9%
9.7%
7.6%
24.9%
Return on equity
57.4%
54.3%
59.4%
55.3%
18.4%
65.5%
78.6%
77.7%
64.6%
164.7%
81.1%
(2,252.9)%
83.1%
40.7%
39.4%
29.1%
150.2%
Plowback ratio
51.8%
46.4%
36.2%
44.1%
(96.1)%
35.3%
16.5%
32.3%
(39.4)%
54.0%
(431.8)%
(155.0)%
(8.4)%
14.9%
30.8%
8.8%
10.9%
Div.&Repurch./FCF
125.7%
149.6%
129.7%
51.8%
60.9%
108.5%
207.7%
84.1%
117.1%
583.8%
116.6%
83.0%
58.2%
66.6%
63.7%
79.2%
52.5%
Forex (GBP/USD)
1.959
1.985
1.463
1.616
1.560
1.554
1.625
1.656
1.557
1.474
1.234
1.351
1.276
1.326
1.367
1.353
1.227
Capital Structure
30 Sep · 2022 | Q3
All numbers in millions
Total liabilities
$ 51,597
Total assets
$ 60,313
Long-term debt
$ 19,322
Cash and equiv.
$ 3,606
Goodwill
$ 7,195
Retained earnings
$ 2,592
Common stock
2,015
Enterprise Value
$ 84,808
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
4,786
6,170
4,135
Receivables
- -
- -
- -
Inventory
5,947
5,996
5,783
Other
8,758
9,466
8,123
Current assets
19,491
20,247
18,674
Acc. Payable
4,144
4,357
4,535
Debt due
6,918
3,725
3,601
Other
12,988
14,066
15,534
Current liabilities
24,050
22,148
23,670
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
0.04%
3.17%
3.17%
Cash flow
(19.04)%
3.93%
58.33%
Earnings
(23.73)%
41.18%
35.44%
Dividends
0.55%
0.59%
1.09%
Book value
3.21%
(1,579.77)%
(722.43)%
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
9,090
7,624
8,646
8,739
34,099
2021
7,418
8,092
9,077
9,527
34,114
2022
9,780
6,929
7,829
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.79
1.14
0.63
0.34
2.89
2021
0.54
0.70
0.58
0.37
2.19
2022
0.90
0.42
5.14
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.47
0.57
0.48
0.48
2.00
2021
0.47
0.58
0.48
0.48
2.00
2022
0.47
0.57
0.35
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Ms. Emma N. Walmsley
Full-time employees:
90,096
City:
Brentford
Address:
980 Great West Road
IPO:
Invalid Date
Website:
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.